GNH USA

Europe — EMA

Kanuma

GNH USA supplies Kanuma (Sebelipase Alfa), a replacement therapy for lysosomal acid lipase deficiency, including Wolman disease and CESD. Request a quote.

Sebelipase Alfa

Request sourcing

1
Pack/s

What is Sebelipase Alfa?

Sebelipase alfa, the active ingredient in Kanuma, is an enzyme replacement therapy presented as a powder for solution for injection for intravenous use. It treats lysosomal acid lipase deficiency, including Wolman disease and cholesteryl ester storage disease.

GNH USA supplies Kanuma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Sebelipase Alfa used for?

Kanuma is used to address the lysosomal acid lipase deficiency pathway and its related disorders.

Lysosomal acid lipase deficiency (LAL‑D): restores deficient enzyme activity to reduce intracellular lipid accumulation. Wolman disease: improves survival and organ function by hydrolyzing cholesteryl esters and triglycerides. Cholesteryl ester storage disease (CESD): decreases hepatic and cardiovascular lipid burden, supporting clinical stability.

What are the side effects of Sebelipase Alfa?

Kanuma may cause a range of adverse reactions.

Common Side Effects: - Infusion‑related reactions (e.g., flushing, chills) - Fever - Nausea - Headache

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity - Significant liver enzyme elevation - Thrombocytopenia - Renal impairment - Immune complex–mediated disease

What precautions apply to Sebelipase Alfa?

Prior to initiating therapy, several safety considerations should be observed.

Monitor liver function: assess hepatic enzymes before and during treatment. Observe for infusion reactions: watch the patient closely during administration. Avoid use in patients with known hypersensitivity to recombinant proteins. Consider dose adjustments in severe hepatic impairment. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Sebelipase Alfa interact with?

Kanuma can interact with other medicines; awareness of potential interactions is important.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy. - Strong immunosuppressants: increased infection risk.

Moderate Interactions (Monitor Closely): - Other enzyme replacement therapies: potential additive effects. - Corticosteroids: may mask infusion‑related reactions. - Hepatically metabolised antibiotics: monitor liver enzymes during co‑administration.

Frequently asked questions

What is Kanuma used for?+
Kanuma is indicated for the treatment of lysosomal acid lipase deficiency, including the severe infantile form known as Wolman disease and the later‑onset cholesteryl ester storage disease. It works by replacing the missing enzyme to reduce harmful lipid accumulation in tissues.
How does sebelipase alfa work?+
Sebelipase alfa is a recombinant form of human lysosomal acid lipase. After intravenous infusion it is taken up by cells and delivered to lysosomes where it hydrolyses cholesteryl esters and triglycerides, thereby clearing stored lipids and restoring normal cellular function.
What is the usual dose of Kanuma?+
The dosing regimen for Kanuma is individualized. A qualified prescriber determines the appropriate dose, infusion rate, and frequency based on the patient’s age, weight, disease severity, and clinical response. No fixed public dosing schedule is provided.
Is Kanuma safe in pregnancy or breastfeeding?+
Safety data for Kanuma in pregnancy and lactation are limited. The product is classified as pregnancy category unknown. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting therapy.
How do I order Kanuma from GNH USA?+
To request Kanuma, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.
How does Kanuma compare with other treatments for LAL‑D?+
Kanuma (sebelipase alfa) is the only enzyme replacement therapy specifically approved for lysosomal acid lipase deficiency. Other approaches are mainly supportive, such as lipid‑lowering agents or dietary management. Compared with supportive care, Kanuma directly addresses the underlying enzyme deficiency, offering disease‑modifying benefits.
What are the storage requirements for Kanuma?+
Kanuma should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.
How is Kanuma administered?+
Kanuma is supplied as a powder for solution for injection. The powder is reconstituted with the appropriate diluent and administered by intravenous infusion over a prescribed period, typically under medical supervision in a hospital or clinic setting.
What are the most serious risks to watch for with Kanuma?+
Serious adverse events include anaphylaxis or severe hypersensitivity reactions, significant elevations in liver enzymes, thrombocytopenia, and renal impairment. Patients should be monitored closely during and after infusion, and any signs of severe reaction should prompt immediate medical attention.
Who should not use Kanuma?+
Kanuma is contraindicated in individuals with a known hypersensitivity to sebelipase alfa or any component of the formulation. Caution is also advised for patients with severe hepatic impairment or those who have experienced severe infusion‑related reactions in the past.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Sebelipase Alfa
Route
Intravenous Use
Manufacturer
Alexion Europe Sas
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU